We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+27.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.42B
AUM Growth
+$256M
(+22%)
Cap. Flow
+$65.4M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
112
New
24
Increased
30
Reduced
36
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$48.1M |
| 2 |
Replimune Group
REPL
|
+$27.8M |
| 3 |
Maravai LifeSciences
MRVI
|
+$27.3M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$25.6M |
| 5 |
Certara
CERT
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$51M |
| 2 |
HMSY
HMS Holdings Corp.
HMSY
|
+$18.7M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 4 |
Aprea Therapeutics
APRE
|
+$17.9M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.8% |
| 2 | Industrials | 1.99% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Guardant Health
GH
$21.8B
| $10.2M | 0.72% |
78,986
-1,400
| -2% | -$161K |
|
|
SGEN
52
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.2M | 0.72% |
58,106
+3,390
| +6% | +$632K |
|
|
PSTX
53
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $9.2M | 0.65% |
838,826
-214,953
| -20% | -$2.27M |
|
54
Bristol-Myers Squibb
BMY
$134B
| $9.03M | 0.64% |
145,574
-52,000
| -26% | -$3.2M |
|
55
Fate Therapeutics
FATE
$294M
| $9M | 0.63% |
+99,000
| New | +$6.15M |
|
56
UnitedHealth
UNH
$378B
| $8.93M | 0.63% |
25,462
| – | – |
|
57
Cytosorbents Corp
CTSO
$23.3M
| $8.81M | 0.62% |
1,104,935
-525,054
| -32% | -$4.39M |
|
58
Natera
NTRA
$38.8B
| $8.75M | 0.62% |
+87,950
| New | +$7.35M |
|
59
Abbott
ABT
$185B
| $8.73M | 0.61% |
79,698
+6,000
| +8% | +$652K |
|
60
Eli Lilly
LLY
$1,000B
| $8.71M | 0.61% |
51,565
| – | – |
|
61
BioMarin Pharmaceuticals
BMRN
$11.6B
| $8.49M | 0.6% |
96,772
-54,550
| -36% | -$4.32M |
|
62
Molina Healthcare
MOH
$10.2B
| $8.08M | 0.57% |
37,972
-19,290
| -34% | -$3.98M |
|
|
CMPI
63
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $8.01M | 0.56% |
548,802
-51,885
| -9% | -$661K |
|
|
AVEO
64
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $6.64M | 0.47% |
1,151,175
+1,051,175
| +1,051% | +$6.02M |
|
65
Cigna
CI
$74.6B
| $5.78M | 0.41% |
27,741
+2,500
| +10% | +$490K |
|
66
Seer Inc
SEER
$123M
| $5.32M | 0.37% |
+94,681
| New | +$6.02M |
|
|
BLU
67
DELISTED
BELLUS Health Inc.
BLU
| $5.19M | 0.37% |
+1,696,940
| New | +$4.6M |
|
68
Amgen
AMGN
$205B
| $5.16M | 0.36% |
22,453
-1,900
| -8% | -$438K |
|
69
Thermo Fisher Scientific
TMO
$215B
| $4.84M | 0.34% |
10,400
+1,750
| +20% | +$821K |
|
70
Medtronic
MDT
$111B
| $4.51M | 0.32% |
38,501
-3,250
| -8% | -$358K |
|
71
Vertex Pharmaceuticals
VRTX
$120B
| $4M | 0.28% |
16,921
+7,050
| +71% | +$1.62M |
|
|
KYNB
72
Kyntra Bio
KYNB
$27.8M
| $3.86M | 0.27% |
4,160
| – | – |
|
73
CRISPR Therapeutics
CRSP
$4.89B
| $3.82M | 0.27% |
+24,970
| New | +$2.95M |
|
|
APLS
74
DELISTED
Apellis Pharmaceuticals
APLS
| $3.72M | 0.26% |
+65,000
| New | +$2.75M |
|
75
Merck
MRK
$316B
| $3.64M | 0.26% |
46,636
-6,288
| -12% | -$481K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sectoral Asset Management held 112 positions worth $1.42B, up 22% from $1.16B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Sectoral Asset Management deployed $65.4M of net new capital in Q4 2020, opening 24 new positions and adding to 30 existing holdings. Its largest new stake was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Aprea Therapeutics, an estimated $17.9M trimmed.
- Sectoral Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
- Sectoral Asset Management added most to Tandem Diabetes Care in Q4 2020, an estimated $25.6M increase.
- Sectoral Asset Management's biggest Q4 2020 reduction was Aprea Therapeutics, cutting an estimated $17.9M.
- Sectoral Asset Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $51M.
- Sectoral Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q4 2020.
- Sectoral Asset Management opened 24 new positions and closed 15 in Q4 2020.
- Sectoral Asset Management's portfolio value rose 22% quarter-over-quarter to $1.42B.
Based on Sectoral Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.